Your browser doesn't support javascript.
loading
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Powles, Thomas; Kockx, Mark; Rodriguez-Vida, Alejo; Duran, Ignacio; Crabb, Simon J; Van Der Heijden, Michiel S; Szabados, Bernadett; Pous, Albert Font; Gravis, Gwenaelle; Herranz, Urbano Anido; Protheroe, Andrew; Ravaud, Alain; Maillet, Denis; Mendez, Maria Jose; Suarez, Cristina; Linch, Mark; Prendergast, Aaron; van Dam, Pieter-Jan; Stanoeva, Diana; Daelemans, Sofie; Mariathasan, Sanjeev; Tea, Joy S; Mousa, Kelly; Banchereau, Romain; Castellano, Daniel.
Afiliação
  • Powles T; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK. t.powles@qmul.ac.uk.
  • Kockx M; HistogeneX N.V, Wilrijk, Belgium.
  • Rodriguez-Vida A; Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.
  • Duran I; Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain.
  • Crabb SJ; Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK.
  • Van Der Heijden MS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Szabados B; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Pous AF; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Gravis G; Institut Paoli-Calmettes, Marseille, France.
  • Herranz UA; Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain.
  • Protheroe A; Department of Medical Oncology, Churchill Hospital, Oxford, UK.
  • Ravaud A; Department of Medical Oncology, Hopital Saint-Andre, University of Bordeaux-CHU Bordeaux, Bordeaux, France.
  • Maillet D; Department of Medical Oncology, Hospital Lyon Sud, Lyon, France.
  • Mendez MJ; Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain.
  • Suarez C; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain.
  • Linch M; Department of Medical Oncology, University College London Hospital, London, UK.
  • Prendergast A; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • van Dam PJ; HistogeneX N.V, Wilrijk, Belgium.
  • Stanoeva D; HistogeneX N.V, Wilrijk, Belgium.
  • Daelemans S; HistogeneX N.V, Wilrijk, Belgium.
  • Mariathasan S; Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium.
  • Tea JS; Genentech, San Francisco, CA, USA.
  • Mousa K; Genentech, San Francisco, CA, USA.
  • Banchereau R; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Castellano D; Genentech, San Francisco, CA, USA.
Nat Med ; 29(12): 3271, 2023 Dec.
Article em En | MEDLINE | ID: mdl-36944799
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido